Journal of the American Medical Association (JAMA)
By Elda Hauschildt
Diuretic therapy, when compared with other hypertensive therapies, is linked to lower combined risk of myocardial infarction (MI) or stroke in hypertension patients who carry the adducin genetic variant.
A United States population-based, case-control study indicates approximately one-third of hypertensive participants carry the adducin variant.
"There was a significant interaction between the presence of the adducin Trp460 variant and the use of diuretics on the risk of the combined outcome of first, non-fatal MI or stroke," say researchers from the University of Washington in Seattle and Leiden University Medical Centre in the Netherlands. They did not find diuretic therapy associated with risk of MI or stroke among 653 carriers of the adducin wild-type genotype